August 21, 2018
Nippon Kayaku said on August 20 that it launched a biosimilar version of the major cancer drug Herceptin (trastuzumab) in Japan the same day after it won approval in March for the treatment of HER-2 overexpressing, unresectable, advanced/relapsed gastric cancer...read more